Interview with Ajit Kamath, Chairman & Managing Director, Arch Pharmalabs
Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD…
Address: 541-A, Arch House, Marol Maroshi Road,
Andheri (E), Mumbai – 400 059, India
Tel: 91-22-33089200/33089400
Web: http://www.archpharmalabs.com/index.asp
We are a pharmaceutical company aligned across two business verticals viz. Products and Services. Our Products business comprises manufacture and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. We have evolved our business and have, over the years, extended from manufacturing APIs and Intermediates to add CRAMS to our offerings, which has significant potential for the growth of our business.
Lipid Lowering Agent
Calcium Channel Blocker
Anti Platelet Agent
Anti hypertensive
Anti anginal
Anti Asthmatic
Anti Histamine
Anti Diabetic
Anti Protozoal
Anti fungal
Oncology
Anti emetic
Proton pump inhibitor
Expectorant
Decongestant
Anti Depressant
Anti Convulsant
Psychostimulant
Hypnotic
Anti parkinsonian
Anti Retroviral
Anti gout
Analgesic
We have evolved to include Contract Research and Manufacturing Services as our growing business vertical. We have developed capabilities to provide a wide range of CRAMS starting from route selection / process development / optimization, analytical development, stability studies, safety studies, scale-up to technology transfer / clinical-trial manufacturing to commercial manufacturing to suit US / EU regulatory requirements. We can cost-effectively manage several complex reactions at various scales of operation, ranging from a few grams to several tonnes. For instance, we, using a proprietary bio-catalytic/ enzymatic technology availed by us, have developed innovative route for the manufacturing of key advanced intermediates.
Arch Pharmalabs started its operations in 1999 when you bought a plant in Hyderabad with a turnover of 2Mn USD. 12 years later, you have grown to a 300Mn USD…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Ananya Chakraborty from the Vydehi Institute of Medical Sciences & Research Centre outlines the key factors behind India’s successful…
The Indian pharma market clocked up double-digit growth of around 15 percent in 2021 (compared to three percent in 2020), driven primarily – but not only – by products related…
The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its pharma arm, the country’s 15 pharma billionaires, Danish CNS firm Lundbeck’s decision to…
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis…
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in the latest national budget; predictions of rapid growth in the coming decade; Cipla’s…
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
See our Cookie Privacy Policy Here